Saturday , January 16 2021

Specialty Pharma Journal Specialty, Precision & Technology

Breaking News

FDA Approves Gavreto for the Treatment of Adults with Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
Incyte Announces Pivotal GEOMETRY mono-1 Study Results of Capmatinib in Patients with METex14 Metastatic Non-Small Cell Lung Cancer Published in NEJM
Natera Announces SMART Study Data for Aneuploidy and 22q Unblinded
Aimmune Agrees to be Acquired by Nestlé Health Science for $2 Billion
Twist Bioscience Announces Potent SARS-CoV-2 Neutralizing Data from COVID-19 Therapeutic Antibody Program
Final Analysis of the Observational GioTag Study: Sequential Afatinib and Osimertinib in Patients with EGFR Mutation-Positive NSCLC
Santhera Exercises Option to Obtain Worldwide Rights to Vamorolone in Duchenne Muscular Dystrophy and All Other Indications
FDA Approves Onureg, a New Oral Therapy, as Continued Treatment for Adults in First Remission with Acute Myeloid Leukemia
FDA Accepts Vertex’s sNDA for Trikafta, Symdeko and Kalydeco for Additional CFTR Mutations
Gilead Sciences and Jounce Therapeutics Announce Exclusive License Agreement for Novel Immunotherapy Program

Tag Archives: SkylineDx

January, 2018

31 January
SkylineDx and Mayo Clinic Enter Strategic Collaboration to Develop Diagnostic Tests for Melanoma

ROTTERDAM, Netherlands, Jan. 31, 2018 /PRNewswire/ — SkylineDx today announced a strategic collaboration with Mayo Clinic to develop novel diagnostic tests which will improve clinical decision making for melanoma patients. For SkylineDx, the collaboration with the renowned Mayo Clinic is an important milestone as it allows the company to develop …
Share

November, 2015

25 November
SkylineDx Receives CE-IVD Mark for its Gene Signature-Based Test for Multiple Myeloma

ROTTERDAM, Netherlands and LAGUNA HILLS, Calif., Nov. 25, 2015 /PRNewswire/ — SkylineDx, today announced they have received CE-IVD registration from the European Competent Authority (Ministry of Health) for the MMprofiler™, the company’s prognostic test to determine the level of risk of a patient with multiple myeloma (MM). SkylineDx is an emerging …
Share